100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43GM133288
Award Date
5/2/19
Completion Date
4/30/22
Dollars Obligated
$298K
Overview
Activity
4
Transactions
4
Subawards
Similar Awards
Federal Agency
National Institute of General Medical Sciences
Awardee
Glycoscientific, L.L.C. (EUVNNWGFCA87)
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Update #1
Update #2
DEVELOPMENT OF SITE-SPECIFIC ARG-GLCNAC ANTIBODIES
Posted 5/2/19
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
DEVELOPMENT OF SITE-SPECIFIC ARG-GLCNAC ANTIBODIES - HUMAN PATHOGENIC GRAM-NEGATIVE BACTERIA, SUCH AS ESCHERICHIA COLI (E. COLI) AND SALMONELLA ENTERICA CAUSE MILLIONS OF DEATHS, THOUSANDS OF FATALITIES AND BILLIONS OF DOLLARS IN MEDICAL EXPENSES AND LOST WAGES. A CRITICAL PROCESS THAT ENABLES THESE ORGANISMS TO OVERCOME THE HOSTS IMMUNE RESPONSE IS THE INJECTION OF PROTEINS DIRECTLY INTO INFECTED MAMMALIAN (HOST) CELLS. SOME OF THESE INJECTED EFFECTORS, FUNCTION AS ENZYMES THAT MODIFY THE STRUCTURE/FUNCTION OF THE HOST PROTEINS, WHICH IN TURN DIMINISH THE CELLS' ABILITY TO FIGHT OFF THE INFECTION. ONE FAMILY OF THESE ENZYMES ARE N-GLYCOSYLTRANSFERASES, WHICH APPEAR TO PLAY CRITICAL, BUT YET UNKNOWN, FUNCTION IN PATHOGENICITY. THESE ENZYMES ADD A SINGLE A-N-ACETYL-D-GLUCOSAMINE (GLCNAC) TO THE GUANIDINIUM GROUPS OF ARGININE RESIDUES. THE PRIMARY FOCUS OF THIS APPLICATION IS TO EVALUATE/DEVELOP METHODOLOGY THAT WILL ENABLE THE GENERATION OF SITE-SPECIFIC A-N-GLCNAC ANTIBODIES. WE FEEL THAT THIS ABILITY WILL OPEN THE DOOR TO THE CREATION OF A WIDE RANGE OF ABS THAT WILL HAVE A WIDE-RANGING IMPACT THE FIELDS OF PHARMACY, MICROBIOLOGY, AND BIOCHEMISTRY.
$0
11/5/22
Not listed
DEVELOPMENT OF SITE-SPECIFIC ARG-GLCNAC ANTIBODIES - HUMAN PATHOGENIC GRAM-NEGATIVE BACTERIA, SUCH AS ESCHERICHIA COLI (E. COLI) AND SALMONELLA ENTERICA CAUSE MILLIONS OF DEATHS, THOUSANDS OF FATALITIES AND BILLIONS OF DOLLARS IN MEDICAL EXPENSES AND LOST WAGES. A CRITICAL PROCESS THAT ENABLES THESE ORGANISMS TO OVERCOME THE HOSTS IMMUNE RESPONSE IS THE INJECTION OF PROTEINS DIRECTLY INTO INFECTED MAMMALIAN (HOST) CELLS. SOME OF THESE INJECTED EFFECTORS, FUNCTION AS ENZYMES THAT MODIFY THE STRUCTURE/FUNCTION OF THE HOST PROTEINS, WHICH IN TURN DIMINISH THE CELLS' ABILITY TO FIGHT OFF THE INFECTION. ONE FAMILY OF THESE ENZYMES ARE N-GLYCOSYLTRANSFERASES, WHICH APPEAR TO PLAY CRITICAL, BUT YET UNKNOWN, FUNCTION IN PATHOGENICITY. THESE ENZYMES ADD A SINGLE A-N-ACETYL-D-GLUCOSAMINE (GLCNAC) TO THE GUANIDINIUM GROUPS OF ARGININE RESIDUES. THE PRIMARY FOCUS OF THIS APPLICATION IS TO EVALUATE/DEVELOP METHODOLOGY THAT WILL ENABLE THE GENERATION OF SITE-SPECIFIC A-N-GLCNAC ANTIBODIES. WE FEEL THAT THIS ABILITY WILL OPEN THE DOOR TO THE CREATION OF A WIDE RANGE OF ABS THAT WILL HAVE A WIDE-RANGING IMPACT THE FIELDS OF PHARMACY, MICROBIOLOGY, AND BIOCHEMISTRY.
$0
11/5/22
Not listed
DEVELOPMENT OF SITE-SPECIFIC ARG-GLCNAC ANTIBODIES
$148.5k
4/28/20
Not listed
DEVELOPMENT OF SITE-SPECIFIC ARG-GLCNAC ANTIBODIES
$150.0k
5/2/19